Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data

NCT06426446 · Unknown status

Last updated 2026-05-28

This study is testing how well a connected device helps track weight loss in adults with severe obesity who are taking Wegovy® over a 6-month period.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) health-services study

Participants 80 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-06 · est. completion 2025-06

Where 1 site · France

What this study is testing ClinicalTrials.gov NCT06426446 ↗

Description as written by the study sponsor.

This study involves collecting real-world data on body weight, body composition, cardiovascular parameters, and neurovegetative parameters using a connected scale in patients with severe obesity treated with Wegovy®.

Treatments tested

Withings Body Comp Pro Device

Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)

Main thing measured	The relative difference in weight loss achieved at 6 months of treatment at the maximum tolerated dose ((weight after 6 months of treatment at the maximum tolerated dose - baseline weight) / baseline weight)
Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06426446 ↗